posted
I started a thread a couple weeks back but it not here anymore?? Anyways here is another PR. Up 163% already.
Inovio Consensus DNA Vaccine Approach Demonstrates 100% Protection Against Unmatched Flu Virus Strains Currently in Circulation
SAN DIEGO--(BUSINESS WIRE)--Jul. 29, 2009-- Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine design, development and delivery, announced today that the company's SynCon™ H1N1 influenza DNA vaccines achieved protection against current circulating swine origin influenza A/H1N1 viruses in animal studies.
IP: Logged |
posted
Inovio Announces $30 Million Registered Direct Offering
SAN DIEGO--(BUSINESS WIRE)--Jul. 30, 2009-- Inovio Biomedical Corporation (NYSE AMEX: INO) (“Inovio”), a leader in DNA vaccine design, development and delivery, announced today that it has received commitments from institutional investors to purchase $30 million of securities in a registered direct offering. Inovio expects to receive net proceeds of approximately $28.5 million after deducting placement agent fees and other offering expenses. Under the terms of a Securities Purchase Agreement, Inovio will sell an aggregate of 11,111,110 shares of its common stock and warrants to purchase up to 2,777,776 additional shares of its common stock. Each unit, consisting of one share of common stock and a warrant to purchase approximately 0.25 of a share of common stock, will be sold for a purchase price of $2.70.
The warrants to purchase additional shares will be exercisable at an exercise price of $3.50 per share beginning six months after issuance and will expire six months from the date they are first exercisable. All of the securities were offered pursuant to an effective shelf registration statement. Proceeds from the transaction will be used for general corporate purposes. Closing of this transaction is subject to the satisfaction of customary conditions.
Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc., (Nasdaq: RODM), acted as the exclusive placement agent for the transaction.
A shelf registration statement relating to the shares of common stock and warrants issued in the offering (and the shares of common stock issuable upon exercise of the warrants) has been filed with the Securities and Exchange Commission (the “SEC”) and has been declared effective. A prospectus supplement relating to the offering will be filed with the SEC. Copies of the prospectus supplement and accompanying prospectus may be obtained directly from the Company by contacting Inovio Biomedical Corporation, 11494 Sorrento Valley Road, San Diego, CA 92121. This announcement is neither an offer to sell nor a solicitation of an offer to buy any of our shares of common stock or warrants. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.
-------------------- Only ONE good stock away from retirement!
IP: Logged |
posted
SAN DIEGO--(BUSINESS WIRE)--Aug. 10, 2009-- Inovio Biomedical Corporation (NYSE Amex:INO), a leader in DNA vaccine design, development and delivery, announced today it has entered into a research collaboration agreement with the National Institutes of Health (NIH)’s Vaccine Research Center (VRC) to develop influenza vaccines. Under the agreement, the VRC and Inovio will pool technologies to develop universal influenza vaccines as well as rapidly advance development of vaccine candidates targeting the emerging pandemic 2009 H1N1 swine flu strains.
-------------------- Only ONE good stock away from retirement!
IP: Logged |
posted
The way America is in love with vaccines, I can see this new DNA type being the future. The question I have is if anyone know if INO has any intent in filing with the FDA. I cannot find anything on a time line.
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Eek!]](eek.gif)
